29 September 2022
These Psoriatic Arthritis (PsA) studies are seeking to determine if the investigational medication deucravacitinib is safe and effective in reducing the symptoms of PsA. These studies are evaluating if deucravacitinib may potentially correct the overactive immune response that causes inflammation in people with PsA.
If eligible, study participants may receive:
Sign up to our newsletter